China Universal Asset Management Company’s Prelude Therapeutics PRLD Stock Holding History

China Universal Asset Management Company’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,076	Closed	-$3.33K	–	472
2023 Q3	$3.33K	Buy	1,076 +389	+57%	+$1.46K	﹤0.01%	411
2023 Q2	$3.09K	Buy	687 +38	+6%	+$227	﹤0.01%	406
2023 Q1	$3.7K	Buy	649 +279	+75%	+$1.7K	﹤0.01%	396
2022 Q4	$2.23K	Sell	370 -78	-17%	-$500	﹤0.01%	364
2022 Q3	$3K	Buy	+448	New	+$3.02K	﹤0.01%	332

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

China Universal Asset Management Company's PRLD Position: Q4 2023 in Review

China Universal Asset Management Company sold out of Prelude Therapeutics (PRLD) in Q4 2023, closing a stake of 1,076 shares — an estimated $3.33K sold.

China Universal Asset Management Company first reported a position in PRLD in Q3 2022 and held it in 5 quarters. The position peaked at $3.7K in Q1 2023. 56 funds tracked by Wall St. Rank hold PRLD as of Q4 2023.

China Universal Asset Management Company reported no remaining Prelude Therapeutics position as of Q4 2023 after selling out during the quarter.
China Universal Asset Management Company sold 1,076 Prelude Therapeutics shares in Q4 2023, an estimated $3.33K.
China Universal Asset Management Company first reported a position in Prelude Therapeutics in Q3 2022 and held it in 5 quarters.
China Universal Asset Management Company's Prelude Therapeutics position peaked at $3.7K in Q1 2023.
56 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2023.

Based on China Universal Asset Management Company's 13F filing for Q4 2023, filed 24 Jan 2024.